<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858245</url>
  </required_header>
  <id_info>
    <org_study_id>16-6001</org_study_id>
    <nct_id>NCT02858245</nct_id>
  </id_info>
  <brief_title>A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device</brief_title>
  <acronym>VELOCITY</acronym>
  <official_title>A Feasibility Registry on Use of Actigraphy Monitoring in Degenerative Mitral Regurgitation (DMR) Subjects Receiving the MitraClip® Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, and multi-centered feasibility registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, and multi-centered feasibility registry (single arm
      study). Approximately 36 subjects with prohibitive risk degenerative mitral regurgitation
      (DMR) who receive at least 1 commercial MitraClip will be registered at approximately 7 US
      sites.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Observational change in daily reported activity levels (counts/min) as assessed by actigraphy, from baseline to 30 days post MitraClip implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Phillips Actiwatch Spectrum PRO is the device being used to capture the primary outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>Pre-procedure, post-procedure, 30 days and 2, 3, 4, 5 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of daily Sleep/Wake by actigraphy</measure>
    <time_frame>Pre-procedure, post-procedure, 30 days and 2, 3, 4, 5 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>Baseline and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation severity</measure>
    <time_frame>Baseline, post-procedure, and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment</measure>
    <time_frame>Baseline, post-procedure, and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance walked 6 minute walk test (6MWT)</measure>
    <time_frame>Baseline &amp; 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>Baseline &amp; 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Mitral Regurgitation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Prohibitive risk degenerative mitral regurgitation (DMR) patients who receive at least 1
        commercial MitraClip
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must consent to receiving the MitraClip device

          -  Subject must consent, be able, and commit to wearing the Actiwatch continuously for
             approximately 7 months

          -  Subject must consent to use of their data from this registry for purposes of
             exploratory research and publication and presentation

        Exclusion Criteria:

          -  Subject is not a member of vulnerable population

          -  Subject must not have any disabilities that preclude reliable data collection from
             the Actiwatch, e.g., epilepsy with uncontrolled recurring episodes, serious stage
             degenerative/disabling disease (e.g. Parkinson's disease), inability to walk or will
             require walking aids, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Staehr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Vascular</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kunal Sampat</last_name>
    <phone>408-845-0746</phone>
    <email>kunal.sampat@av.abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bradley White</last_name>
    <phone>616-443-2812</phone>
    <email>bradley.white@av.abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramon Quesada, MD</last_name>
      <phone>786-596-2959</phone>
      <email>ramonq@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Goessl, MD</last_name>
      <phone>612-863-8097</phone>
      <email>mario.goessl@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation for Medical Education and Research</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mackram F Eleid, MD</last_name>
      <phone>507-284-3545</phone>
      <email>eleid.mackram@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael J Rinaldi, MD</last_name>
      <phone>704-355-4794</phone>
      <email>michael.rinaldi@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours St Mary's Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott D Lim, MD</last_name>
      <phone>434-982-1058</phone>
      <email>sl9pc@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>July 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
